Immunome (IMNM) Corporate presentation summary

Strategic vision and positioning

• Aims to establish a premier targeted oncology company with a focus on breakthrough therapies and a robust early-stage pipeline leveraging proprietary HC74 payload technology.

• Positioned to deliver multiple INDs per year, supported by an experienced leadership team and a cash runway expected to extend into 2028.

Lead asset: Varegacestat for desmoid tumors

• Oral, once-daily gamma secretase inhibitor demonstrated positive Phase 3 topline data, meeting primary and all key secondary endpoints.

• Achieved 84% reduction in risk of progression or death vs placebo (HR 0.16, p<0.0001), with a 56% objective response rate and 83% median tumor volume reduction.

• Generally well-tolerated safety profile; most adverse events were grade 1 or 2, with no deaths reported.

• NDA submission planned for 2Q 2026, aiming to become the new standard of care for desmoid tumors.

Market opportunity and launch strategy

• Desmoid tumors are rare, locally aggressive, and debilitating, with limited approved systemic therapies and high recurrence rates.

• Launch strategy targets patient initiation, sustained adherence, and expansion across sarcoma centers of excellence, addressing a US market of 10,000–11,000 actively managed patients.